Anti-Human IL-32 (Intermediate Domain)
| Code | Size | Price |
|---|
| LEI-I-505-20ug | 20 ug | £199.00 |
Quantity:
| LEI-I-505-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Antigen Distribution:
IL-32 is expressed on activated lymphocytes and NK cells.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:I-517
Long Description:
IL-32 is approximately 26kD and is a pro-inflammatory cytokine that can induce cells of the immune system to secrete inflammatory cytokines including TNFα. IL-32 can also support osteoclast differentiation by regulating the MAPK/ERK pathway and the actin cytoskeleton. IL-32 can exist in at least four differentially spliced isoforms (α, β, γ and δ) with IL-32α being the shortest and most abundant of the four variants. Remarkably, it does not share sequence homology with known cytokine families and is highly expressed in immune tissues. Elevated levels of IL-32 are present in patients with coronary artery disease and endometriosis and may play a role in other autoimmune and inflammatory diseases such as rheumatoid arthritis. In a recent lung cancer study, the inhibitory effects of IL-32γ on tumor development were associated with inhibition of the STAT5 pathway which ultimately demonstrated that IL-32γ negatively regulates tumor development suggesting that IL-32γ has therapeutic potential for use in the treatment of cancer progression.
NCBI Gene:
9235
Target:
IL-32
References
1. Dahl, CA. et al. (1992) Immunol. 148:5972. Kim, SH. et al. (2005) Immunity 22:1313. Cagnard, N. et al. (2005) Eur. Cyto. Network 16:289
Related Products
| Product Name | Product Code | Supplier | Anti-Human IL-32 (CT) | LEI-I-504 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|